Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity

被引:6
|
作者
Ding, Hao [1 ]
Liu, Xiao-Chang [1 ]
Mei, Qiao [1 ]
Xu, Jian-Ming [1 ]
Hu, Xiang-Yang [2 ]
Hu, Jing [1 ]
机构
[1] Anhui Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Hefei 230022, Anhui, Peoples R China
[2] Anhui Med Univ, Affiliated Hosp 1, Dept Pathol, Hefei 230022, Anhui, Peoples R China
关键词
Mesalamine suppositories; Hypersensitivity; Ulcerative colitis; Surgery; Sulfasalazine; 5-AMINOSALICYLIC ACID; MESALAZINE; EXACERBATION; TRIAL;
D O I
10.3748/wjg.v20.i13.3716
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Mesalamine suppositories have been used widely for the treatment of distal ulcerative colitis and considered to be safer than systemic administration for its limited systemic absorption. However, previous studies have shown that mesalamine suppository occasionally causes severe hypersensitivity reactions including fever, rashes, colitis exacerbation and acute eosinophilic pneumonia. Here we present a 25-year-old woman with ulcerative colitis with bloody diarrhea accompanied by abdominal pain and fever which were aggravated after introduction of mesalamine suppositories. In light of symptom exacerbation of ulcerative colitis, increased inflammatory injury of colon mucosa shown by colonoscopy and elevated peripheral eosinophil count after mesalamine suppositories administration, and the Naranjo algorithm score of 10, the possibility of hypersensitivity reaction to mesalamine suppositories should be considered, warning us to be aware of this potential reaction after administration of mesalamine formulations even if it is the suppositories. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码:3716 / 3718
页数:3
相关论文
共 50 条
  • [41] Drug-induced hypersensitivity syndrome with lupus manifestations due to mesalazine in a patient with ulcerative colitis
    Zgheib, Omar
    Trombert, Veronique
    Jandus, Peter
    Serratrice, Christine
    BMJ CASE REPORTS, 2022, 15 (02)
  • [42] Long-term Safety and Tolerability of Once-daily Mesalamine Granules in the Maintenance of Remission of Ulcerative Colitis
    Lichtenstein, Gary R.
    Barrett, Andrew C.
    Bortey, Enoch
    Paterson, Craig
    Forbes, William P.
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (08) : 1399 - 1406
  • [43] Treatment of ulcerative colitis with oral mesalamine: Advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention
    Sandborn, William J.
    REVIEWS IN GASTROENTEROLOGICAL DISORDERS, 2006, 6 (02) : 97 - 105
  • [44] NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis
    Hausmann, M.
    Paul, G.
    Menzel, K.
    Brunner-Ploss, R.
    Falk, W.
    Schoemerich, J.
    Herfarth, H.
    Rogler, G.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2008, 46 (03): : 259 - 265
  • [45] A Review of Delayed-Release MMX Mesalamine: It's Use in the Treatment of Ulcerative Colitis
    Sharaiha, Reem
    Swaminath, Arun
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 45 - 51
  • [46] SAFETY AND EFFICACY OF CONTROLLED-RELEASE MESALAMINE FOR MAINTENANCE OF REMISSION IN ULCERATIVE-COLITIS
    MINER, P
    HANAUER, S
    ROBINSON, M
    SCHWARTZ, J
    ARORA, S
    BRIGGS, RL
    LAWLIS, V
    FELGER, C
    KITZMILLER, G
    LIEBERMANN, T
    FRACHTMAN, R
    FISCHER, C
    CELLO, JP
    GRENDELL, J
    SATOW, J
    HANAUER, SB
    HANAN, I
    SCHULTZ, P
    JAMES, D
    MERTESDORF, J
    HIESTAND, F
    TUCKER, P
    ROBERTS, T
    BRUNDAGE, P
    GRIFFIN, T
    BECK, JE
    RICK, G
    HARTONG, W
    BUSER, W
    BRAND, S
    BRYANT, P
    KLIEWER, M
    MELLOW, M
    MCFADDEN, R
    NEUMANN, D
    HELIN, K
    PRIVETTCOINTEPAS, CJ
    MEEK, RR
    ROUFAIL, W
    BRICE, R
    HUGHES, TP
    FINA, M
    MURPHY, D
    CLINARD, L
    ALLMAN, D
    BOWEN, B
    SCHWARTZ, JL
    JURCIK, I
    WHITE, LB
    COHEN, M
    DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (02) : 296 - 304
  • [47] Ulcerative colitis occurring, in the course of rheumatoid arthritis: A case successfully treated with mesalamine enema
    Sugisaki, K
    Honma, F
    Iwadate, H
    Shio, K
    Shioya, Y
    Fukaya, E
    Sato, K
    Saito, H
    Sekine, H
    Kobayashi, H
    Orikasa, H
    Watanabe, H
    Sato, Y
    INTERNAL MEDICINE, 2004, 43 (11) : 1046 - 1050
  • [48] Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial
    Ben-Horin, Shomron
    Har-Noy, Ofir
    Katsanos, Konstantinos H.
    Roblin, Xavier
    Chen, Minhu
    Gao, Xiang
    Schwartz, Doron
    Cheon, Jae Hee
    Cesarini, Monica
    Bojic, Daniela
    Protic, Marijana
    Theodoropoulou, Angeliki
    Abu-Kaf, Heba
    Engel, Tal
    Tang, Jian
    Veyrard, Pauline
    Lin, Xiaoqing
    Mao, Ren
    Christodoulou, Dimitrios
    Karmiris, Konstantinos
    Knezevic-Ivanovski, Tamara
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (12) : 2868 - +
  • [49] Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX (R) mesalamine
    Nanda, Kavinderjit
    Moss, Alan C.
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2012, 4 : 41 - 50
  • [50] Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease
    Doherty, Glen A.
    Peppercorn, Mark A.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2009, 2 : 139 - 147